slides · global inventory
Quote
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 18,554
Current window 14,971-15,000
Pages 619
Rows per page 30
Component
14,971-15,000 of 18,554
156
The slide uses a combination of narrative analysis and a specific case study excerpt to challenge the safety profile of pitolisant.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
157
The slide presents clinical case summaries to address potential safety concerns regarding cardiac events.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
160
The slide highlights the FDA's 'wait-and-see' posture and specific concerns about seizures as a safety signal for the drug pitolisant.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
161
The slide uses a 'fraud-exposure' or 'investigative' tone to question the lack of public data on a specific study.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
163
The slide uses a 'villain' narrative to frame the company's non-disclosure as intentional concealment.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
164
The slide uses a combination of original analysis and cited medical literature to challenge the transparency of clinical trial reporting.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
165
The slide uses a 'preempt_rebuttal' strategy by highlighting a specific safety concern (eosinophilic abnormality) that the authors claim was ignored in official FDA review documents.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
166
The slide uses a scientific table to challenge the 'no appreciable binding' claim found in a drug's package insert, citing reproducibility concerns regarding the source of that claim.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
167
The slide uses a medical reference to re-frame clinical trial data that was previously dismissed as unrelated.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
168
The slide uses specific case descriptions to argue for a pattern of respiratory/pulmonary-related deaths.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
169
The slide uses a direct quote from an FDA clinical review to demonstrate a lack of oversight regarding a specific medical signal.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
170
The slide uses a combination of narrative argument and a cited abstract to highlight a potential safety oversight.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
171
The slide uses two distinct text columns to present evidence from 2008 and 2009 papers regarding the toxicity profile of H3R compounds.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
172
The slide uses a specific medical case study to establish a pattern of misdiagnosis and severity, linking it to the current subject (pitolisant).Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
181
The slide presents a clinical case narrative alongside screenshots of FDA FAERS database records.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
183
The slide presents a clinical case study narrative, likely for pharmacovigilance or safety analysis.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
184
The slide highlights a potential cover-up or reporting discrepancy regarding a patient seizure.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
185
The slide presents a narrative summary of a medical case report, pointing out suspicious physician/company behavior regarding the reporting of heart palpitations.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
186
The slide presents a clinical case study from the FDA FAERS database, highlighting a potential drug-drug interaction or confounding factor.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
187
This is a clinical case report document from the FDA Adverse Event Reporting System (FAERS).Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
188
This is a raw FDA FAERS FOIA case report document.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
189
The slide presents a clinical case study analysis of a specific adverse event report (FAERS).Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
191
The slide highlights a discrepancy between patient belief and sponsor assessment regarding drug causality.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
193
The slide uses a narrative structure to expose a potential cover-up or reporting failure regarding a serious adverse event.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
194
This is a medical case report summary, likely used for pharmacovigilance or safety analysis.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
195
This is a pharmacovigilance case report summary.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
196
The slide presents a specific pharmacovigilance case report, highlighting a positive dechallenge.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
197
This is a clinical case study/adverse event report sourced from FDA FAERS data.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
198
This appears to be a medical case report document from the FDA FAERS database.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
199
This is a clinical case study/adverse event report sourced from FDA FAERS data.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit